Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-06-07
1998-12-01
Kight, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514885, 53612313, A61K 31715, A61K 3172, A61K 3173
Patent
active
058439188
ABSTRACT:
Disclosed are lipid A analogs useful for the treatment of septic shock and LPS-mediated activation of viral infection.
REFERENCES:
patent: 4495346 (1985-01-01), Anderson et al.
patent: 4844894 (1989-07-01), Ribi
patent: 4912094 (1990-03-01), Myers et al.
patent: 4918163 (1990-04-01), Young et al.
patent: 4929604 (1990-05-01), Munford et al.
patent: 5013661 (1991-05-01), Munford et al.
patent: 5041427 (1991-08-01), Takayama et al.
patent: 5057598 (1991-10-01), Pollack et al.
patent: 5066794 (1991-11-01), Shiba
patent: 5134230 (1992-07-01), Kusama et al.
patent: 5158939 (1992-10-01), Takayama et al.
patent: 5158941 (1992-10-01), Jadhav et al.
patent: 5191072 (1993-03-01), Hasegawa et al.
Brinder et al., "123, Glycosylphosphonates of 2-Amino-2-Deoxy-Aldoses. Synthesis of a Phosphonate Analogue of Lipd X.sup.1 ", Helvetica Chimica Acta 70:1341-1357, 1987.
Bone et al., "A Controlled Clinical Trial of High-Dose Methylprednisolone in the Treatment of Severe Sepsis and Septic Shock", The New England Journal of Medicine 317:653-658, 1987.
Hampton et al., "Lipid A Binding Sites in Membranes of Macrophage Tumor Cells", J. of Biol. Chem. 263:14802-14807, 1988.
Hinshaw et al., "Effect of High-Dose Glucocorticoid Therapy on Mortality in Patents with Clinical Signs of Systemic Sepsis", The New England Journal of Medicine 317:659-665, 1987.
Kinzy et al., "Synthesis of Glycopeptides of the Mucin Type Containing A .beta.-D-GlepNAc-(1.fwdarw.3)-D-GalpNAc Unit", Carbohydrate Research 193:33-47, 1989.
Kirkland et al., "Diphosphoryl Lipid A Derived from Lipopolysaccharide (LPS) of Rhodopseudomonas sphaeroides Inhibits Activation", Infection and Immunity 59:131-136, 1991.
Krauss et al., "Structural Analysis of the Nontoxic Lipid A of Thodobacter Capsulatus 37b4", Eur. J. Biochem. 180:519-526, 1989.
Lei et al., "I. Detection of Lipopolysaccahride-Binding Sites on Splenocytes and Splenocyte Subpopulations", J. of Immunology 996-1005, 1988.
Lei et al., "II. Membrane Localization and Binding Characteristics", The J. of Immunology 141:1006-1011, 1988.
Qureshi et al., "Diphosphoryl Lipid A Obtained from the Nontoxic Lipopolysaccharide of Rhodopseudomonas Sphaeroides is an Endotoxin Antagonist in Mice", Infection and Immunity 59:441-444, 1991.
Roeder et al., "Endotoxic-Lipopolysaccharide-Specific Binding Proteins on Lymphoid Cells of Various Animal Species: Association with Endotoxin Susceptibility", Infection and Immunity 57:1054-1058, 1989.
Takayama et al., "Diphosphoryl Lipid A from Rhodopseudomonas Sphaeroides ATCC 17023 Blocks Induction of Cachectin in Macrophages by Lipopolysaccharide", Infection and Immunity 57:1336-1338, 1989.
Toepfer et al., "Muramic Acid Derivatives as Glycosyl Donors for the Synthesis of Muramyl-Containing Glycosphingolipids and Fatty Acids", Carbohydrate Resarch 202:193-205, 1990.
Wright et al., "CR3 (CD11b/CD18) Expresses One Binding Site for Arg-Gly-Asp-Containing Peptides and a Second Site for Bacterial Lipopolysaccharide", J. Exp. Med. 169:175-183, 1989.
Ziegler et al., "Treatment of Gram-Negative Bacteremia and Shock with Human Antiserum to a Mutant Escherichia Coli", The New England Journal of Medicine 307:1225-1230, 1982.
Asano Osamu
Christ William J.
Hawkins Lynn D.
Kawata Tsutomu
Kobayashi Seiichi
Eisai Co. Ltd.
Kight John
Lee Howard C.
LandOfFree
Anti-endotoxin compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-endotoxin compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-endotoxin compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2395729